On Jul. 23, 2020, Novavax and FUJIFILM Diosynth Biotechnologies announced an agreement to manufacture bulk drug substance for NVX-CoV2373, Novavaxﾒ COVID-19 vaccine candidate. FDBﾒs site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373.